Company news
Abcellera Biologics Inc. (NASDAQ:ABCL) news
Abcellera Biologics Inc. news releases on 6ix. Latest, Feb 11, 2021: AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
Press releases — page 4
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
February 10, 2021
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
February 8, 2021
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call
February 2, 2021
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
January 26, 2021
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
January 25, 2021
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
January 20, 2021
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
January 18, 2021
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
December 20, 2020
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
December 14, 2020
AbCellera Announces Pricing of Initial Public Offering
December 9, 2020